Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors whose incidence has increased steadily over the past decades. Octreotide is a somatostatin analogue which has traditionally been used for the relief of symptoms that result from the release of peptides and amines (carcinoid syndrome), although a substantial amount of evidence suggests that it has anti-proliferative effects and lengthens the time to progression of the disease. We’ve aimed to evaluate the relationship between octreotide use and progression-free survival (PFS) and overall survival (OS). Medical records of 76 patients with gastroenteropancreatic NENs treated with long-acting octreotide in the University Hospital Centre Zagreb and University Hospital Center Sisters of Charity were collected in the period from March 2011 to March 2019. A retrospective analysis was completed with the Kaplan-Meier method using the PFS and OS as a primary endpoint. Previous to octreotide treatment patients had confirmed high expression of somatostatin receptors (sst-rs) by tetroktyde scintigraphy. All patients were followed for a median of 38 months, all of them where grade 1 (27%) or grade 2 (73%). Median PFS for all patients was estimated at 12 ± 2,5 months (95% CI 9,62-14,38). Median PFS for patients with pancreatic NETs was estimated at 10 ± 0,5 months (95% CI 7,03-12,97; median Ki-67 10%), patients with NET of large intestine at 10 ± 3,67 months (95% CI 2,87-17,13; median Ki-67 14%), patients with NETs of unknown primary at 12 ± 2,6 months (95% CI 4,93-19,07; median Ki-67 6%) and for patients with NETs of small intestine at 30 ± 14,5 months (95% CI 1,57-58,48; median Ki-67 5%). Median OS was not reached in any subgroup of patients. Although overall median PFS is lower than in the PROMID study, the fact that the median OS was not reached renders long-acting octreotide as an effective treatment option with acceptable tolerability. This patient population was more heterogenous than in clinical trials and reflects the real-life setting of clinical practice.